Seres Therapeutics, Inc. operates as a microbiome therapeutics platform company. The Company focuses on developing biological drugs, which are designed to restore health by repairing the function of a dysbiotic microbiome. Seres Therapeutics also conducts research on metabolic diseases.

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Seres Therapeutics (MCRB US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

424B3 | Prospectus

S-3 | Registration statement for specified transactions by certain issuers

Current Report (Form 8-K | Period ending 2024-09-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)